DRG Market Assessment reports

Clarivate Epidemiology’s coverage of axial spondyloarthritis (AxSpA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key AxSpA patient populations covering 171 countries and more than 99%…

Clarivate Epidemiology’s coverage of hemophilia B comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…

Prophylactic therapy for migraine is prescribed to reduce the frequency, severity, and duration of migraine attacks and to increase the responsiveness of these attacks to acute treatment. Generic…

Clarivate Epidemiology’s coverage of hemophilia A comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…

Immune checkpoint inhibitors continue to dominate the treatment of non-small cell lung cancer (NSCLC), and biomarker-based approaches are increasingly segmenting the space and providing new…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key hemophilia A patient population covering 171 countries and more than…

Clarivate Epidemiology’s coverage of hospital-treated gram-negative infections (HT-GNIs) comprises epidemiological estimates of nine types of infections: urinary tract infections, bloodstream…

In the last decades, markedly improved survival benefit has been achieved in the treatment of advanced or metastatic HER2-positive breast cancer. Effective HER2-targeted drugs such as Herceptin,…

Clarivate Epidemiology’s coverage of myelodysplastic syndromes (MDS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key MDS patient populations, covering 171 countries and more than 99% of…

Clarivate Epidemiology’s coverage of myelodysplastic syndromes (MDS) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed…